dasatinib
Dasatinib is a dual inhibitor of the src and abl tyrosine kinases. It was approved by the Federal Drug Administration for the treatment of imatinib mesylate-resistant chronic myeloid leukemia.
Copyright humpath.com, website in human pathology | Web design by PBCom.net